Efficacy and safety of insulin glargine 300 U/mL in people with T2D in China: the INITIATION study

被引：0
|
作者：
Chen, L. [1 ,2 ]
Wan, H. [3 ]
Han, J. [4 ]
Yang, C. [5 ]
Shao, H. [6 ]
Li, J. [7 ]
Yan, W. [8 ]
Zhang, M. [9 ]
Li, M. [10 ]
Han, Y. [10 ]
Kang, L. [10 ]
机构：
[1] Chu Hsien I Mem Hosp, Tianjin Key Lab Metab Dis, NHC Key Lab Hormones & Dev, Tianjin, Peoples R China
[2] Tianjin Med Univ, Tianjin Inst Endocrinol, Dept Endocrinol, Tianjin, Peoples R China
[3] Panjin Cent Hosp, Dept Endocrinol, Panjin, Peoples R China
[4] Hebei PetroChina Cent Hosp, Dept Endocrinol, Langfang, Peoples R China
[5] Guangzhou Med Univ, Affiliated Hosp 6, Qingyuan Peoples Hosp, Dept Endocrinol, Qingyuan, Peoples R China
[6] Nankai Univ, Tianjin Ctr Hosp 4, Dept Endocrinol, Tianjin, Peoples R China
[7] Ningbo Univ, Affiliated Hosp 1, Dept Endocrinol & Metab, Ningbo, Peoples R China
[8] Huadu Dist Peoples Hosp Guangzhou, Dept Endocrinol, Guangzhou, Peoples R China
[9] Sanofi Investment Co Ltd, Med RWE, Shanghai, Peoples R China
[10] Sanofi Investment Co Ltd, Med Diabet, Shanghai, Peoples R China
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2024年 / 209卷
关键词：
D O I：
10.1016/j.diabres.2024.111432
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
IDF23-0184
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of insulin glargine 300 U/mL in people with T2D in China: subanalysis of the INITIATION study
    Chen, L.
    Wen, B.
    Liu, H.
    Wu, H.
    Duan, B.
    Shu, H.
    Zhang, Q.
    Zhang, M.
    Li, M.
    Han, Y.
    Kang, L.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
  • [2] Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: The INITIATION study
    Chen, Liming
    Wen, Binhong
    Liu, Haixia
    Wu, Hongmei
    Duan, Binhong
    Shu, Hongyan
    Zhang, Qiu
    Wu, Xiaohong
    Li, Min
    Han, Yanfang
    Kang, Lei
    Zhang, Minlu
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4571 - 4582
  • [3] Efficacy and safety of switching to insulin glargine 300 U/mL in people with type 2 diabetes uncontrolled on basal insulin in China: A post hoc subpopulation analysis of the INITIATION study
    Chen, Liming
    Wan, Hailong
    Han, Jie
    Yang, Caixian
    Shao, Hailin
    Li, Jialin
    Yan, Wensheng
    Xiao, Jianzhong
    Sun, Yadong
    Li, Min
    Han, Yanfang
    Kang, Lei
    Zhang, Minlu
    DIABETES OBESITY & METABOLISM, 2025, 27 (03): : 1423 - 1431
  • [4] Real-World Health Outcomes in Patients with T2D Initiating Insulin Glargine 300 U/mL vs. Insulin Glargine 100 U/mL in a Specialist Endocrinology Practice
    Abitbol, Alexander
    Brown, Ruth E.
    Jiandani, Dishay
    Aronson, Ronnie
    DIABETES, 2017, 66 : A272 - A272
  • [5] Efficacy and safety of iGlarLixi vs insulin glargine 100 U/ml in Chinese people with type 2 diabetes (T2D) inadequately controlled on basal insulin (BI): LixiLan-L-China trial
    Guo, X.
    Zhang, J.
    Dong, X.
    Lu, Y.
    Pang, W.
    Gu, S.
    Ping, L.
    Nian, G.
    Niemoeller, E.
    Souhami, E.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 270 - 270
  • [6] REAL-WORLD EVIDENCE DEMONSTRATES COMPARABLE CLINICAL OUTCOMES OF SWITCHING FROM INSULIN GLARGINE 100 U/ML TO INSULIN GLARGINE 300 U/ML VS INSULIN DEGLUDEC IN T2D PATIENTS
    Blonde, L.
    Zhou, F. L.
    Bosnyak, Z.
    Westerbacka, J.
    Gupta, V. E.
    Sharma, R. K.
    Bailey, T. S.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A137 - A138
  • [7] Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
    Gourdy, Pierre
    Bahloul, Amar
    Boultif, Zahra
    Gouet, Didier
    Guerci, Bruno
    DIABETES THERAPY, 2020, 11 (01) : 147 - 159
  • [8] Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
    Pierre Gourdy
    Amar Bahloul
    Zahra Boultif
    Didier Gouet
    Bruno Guerci
    Diabetes Therapy, 2020, 11 : 147 - 159
  • [9] Reduced hypoglycemia and comparable efficacy with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in subjects with T2D achieving different levels of pre-breakfast SMPG
    Reid, Timothy
    Odugbesan, Ola
    Gill, Jasvinder
    Nikonov, Elena
    Chao, Jason
    Bailey, Timothy
    PHARMACOTHERAPY, 2016, 36 (12): : E231 - E231
  • [10] Insulin glargine 300 U/mL safety data in pregnancy
    Westerbacka, Jukka
    Duverne, Marielle
    Grulovic, Natasa
    Thummisetti, Sreenivas
    Doder, Zoran
    DIABETES OBESITY & METABOLISM, 2025, 27 (05): : 2322 - 2325
12345